Cited by 117Obstructive Sleep Apnea ResearchHealth Systems, Economic Evaluations, Quality of LifeSleep and related disorders

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Cost-effectiveness of using continuous positive airway pressure in the treatment of severe obstructive sleep apnoea/hypopnoea syndrome in the UK

Open access
Guest, J F, Helter, M T, Morga, A, Stradling, J R·2008·Thorax

Abstract

OBJECTIVE: A study was undertaken to estimate the cost-effectiveness of using continuous positive airway pressure (CPAP) in the management of patients with severe obstructive sleep apnoea/hypopnoea syndrome (OSAHS) compared with no treatment from the perspective of the UK's National Health Service (NHS). METHODS: A Markov model was constructed to assess the cost-effectiveness of CPAP compared with no treatment. The model depicted the management of a 55-year-old patient with severe OSAHS as defined by an apnoea-hypopnoea index (AHI) >30 and daytime sleepiness (Epworth Sleepiness Scale score >or=12). The model spans a period of 14 years. RESULTS: According to the model, 57% of untreated patients are expected to be alive at the end of 14 years compared with 72% of patients treated with CPAP. Untreated patients are expected to cost the NHS pound10 645 (95% CI pound7988 to pound14,098) per patient over 14 years compared with pound9672 (95% CI pound8057 to pound12,860) per CPAP-treated patient. Treatment with CPAP for a period of 1 year was found not to be a cost-effective option since the cost per quality-adjusted life year (QALY) gained is expected to be > pound20,000, but after 2 years of treatment the cost per QALY gained is expected to be pound10,000 or less and, after 13 years of treatment, CPAP becomes a dominant treatment (ie, more effective than no treatment for less cost). CONCLUSION: Within the limitations of the model, CPAP was found to be clinically more effective than no treatment and, from the perspective of the UK's NHS, a cost-effective strategy after a minimum of 2 years of treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/thx.2007.086454

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Guest et al. estimated that cost savings exceeded the costs of treating OSA after 13 years.

    “For example, Guest et al. estimated that cost savings exceeded the costs of treating OSA after 13 years.141”

    From International Consensus Statement on Obstructive Sleep Apnea (2023) · cites this paper as [141]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Metadata

Authors
Guest, J. F., Helter, M. T., Morga, A., & Stradling, J. R.
Affiliations
  • Catalyst Health Economics Consultants Ltd (GB)
  • Churchill Hospital (GB)
Corresponding author
Guest, J F
Venue
Thorax
Publisher
BMJ
Published
2008-10-01
Volume
63
Issue
10
Pages
860-865
ISSN
0040-6376 (ISSN-L)
OpenAlex
W2151295847
Cited by
117
References
22
Citations by year
2025: 6 · 2024: 10 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 6 · 2019: 6 · 2018: 5 · 2017: 6 · 2016: 9 · 2015: 6 · 2014: 8 · 2013: 13 · 2012: 5
FWCI
4.29
Type
journal article
Language
en
Open access
Locations
  • Thorax (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
ResMed
Topics
  • Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
Keywords
continuous positive airway pressure, obstructive sleep apnea, cost-effectiveness, Markov model, cost per quality-adjusted life year, National Health Service, apnea-hypopnea index, daytime sleepiness, long-term survival
MeSH terms
Accidents, Traffic, Cardiovascular Diseases, Cost-Benefit Analysis, Humans, Patient Compliance, Health Care Costs, Quality-Adjusted Life Years, Sleep Apnea, Obstructive, Continuous Positive Airway Pressure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review